Despite Granting A Request For Rehearing, The PTAB Maintained Its Finding That Teva's Copaxone Claims Were Unpatentable As Obvious, PTAB Litigation Blog
Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
In granting rehearing in part, the PTAB vacated its original decisions and concurrently entered modified Final Written Decisions maintaining that the challenged claims are unpatentable...
To print this article, all you need is to be registered or login on Mondaq.com.
In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC
v. Yeda Research & Development Co. Ltd.,IPR2015-00643; -00644; -00830, the PTAB
granted-in-part Patent Owner Teva's request for rehearing of
the Final Written Decisions finding every claim of the challenged
patents obvious over the prior art. In granting rehearing in
part, the PTAB vacated its original decisions and concurrently
entered modified Final Written Decisions maintaining that the
challenged claims are unpatentable as obvious over the prior
art.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
Despite Granting A Request For Rehearing, The PTAB Maintained Its Finding That Teva's Copaxone Claims Were Unpatentable As Obvious, PTAB Litigation Blog
United StatesIntellectual Property
Contributor
Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
